Last reviewed · How we verify
Cycloset
At a glance
| Generic name | Cycloset |
|---|---|
| Also known as | Bromocriptine Mesylate Quick Release, bromocriptine mesylate |
| Sponsor | Eastern Virginia Medical School |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dopamine Action on Metabolism in Relation to Genotype (PHASE2)
- A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets (PHASE3)
- Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy (PHASE4)
- Bromocriptine for Patients With Schizophrenia and Prediabetes (PHASE4)
- Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease (PHASE1, PHASE2)
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa (EARLY_PHASE1)
- Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cycloset CI brief — competitive landscape report
- Cycloset updates RSS · CI watch RSS
- Eastern Virginia Medical School portfolio CI